Jiang Y, et al. - In this economic modelling analysis, experts assessed the cost-efficiency of the 9-valent human papillomavirus (HPV) vaccine for the prevention of cervical cancer in China. At the current price, in comparison with the quadrivalent and the bivalent vaccines for young girls in China who had not been formerly infected with HPV, the 9-valent HPV vaccine was observed to be not cost-efficient. Thus, regarding the economic profile of the 9-valent vaccine, policymakers and clinicians should keep potential vaccine recipients notified and should carefully acknowledge expanding its use in China at the current price.